Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Acute transverse myelitis (ATM) is a severe complication of systemic lupus erythematosus (SLE). This study evaluated the clinical factors related to outcome in patients with SLE-associated ATM. Methods: The medical records of patients diagnosed with SLE-associated ATM between January 1995 and January 2015 were reviewed. The patients were divided into two groups based on improvement of neurological deficits after treatment: favorable response group and unfavorable response group. During follow-up, the recurrence of ATM was also analyzed. Results: ATM was identified in 16 patients with SLE. All of the patients were treated with high doses of methylprednisolone (≥ 1 mg/kg daily). Although 12 patients (75%) recovered (favorable response group), four (25%) had persistent neurologic deficits (unfavorable response group) after the treatment. Compared to the favorable response group, significantly higher Systemic Lupus Erythematosus Disease Activity Index-2000, lower complement levels and initial severe neurologic deficits were found in the unfavorable response group. Among the 12 favorable response patients, five (41.7%) experienced recurrence of ATM during the followup. Patients (n = 5) who experienced relapse had a shorter duration of high-dose corticosteroid treatment (13.2 days vs. 32.9 days, p = 0.01) compared to patients who did not relapse. The mean duration of tapering-off the corticosteroid until 10 mg per day was significantly longer in non-relapse group (151.3 ± 60.8 days) than in relapse group (63.6 ± 39.4 days, p = 0.013). Conclusions: Higher disease activity in SLE and initial severe neurologic deficits might be associated with the poor outcome of ATM. Corticosteroid slowly tapering- off therapy might be helpful in preventing the recurrence of ATM.
Abstract
Background/Aims: Acute transverse myelitis (ATM) is a severe complication of systemic lupus erythematosus (SLE). This study evaluated the clinical factors related to outcome in patients with SLE-associated ATM. Methods: The medical records of patients diagnosed with SLE-associated ATM between January 1995 and January 2015 were reviewed. The patients were divided into two groups based on improvement of neurological deficits after treatment: favorable response group and unfavorable response group. During follow-up, the recurrence of ATM was also analyzed. Results: ATM was identified in 16 patients with SLE. All of the patients were treated with high doses of methylprednisolone (≥ 1 mg/kg daily). Although 12 patients (75%) recovered (favorable response group), four (25%) had persistent neurologic deficits (unfavorable response group) after the treatment. Compared to the favorable response group, significantly higher Systemic Lupus Erythematosus Disease Activity Index-2000, lower complement levels and initial severe neurologic deficits were found in the unfavorable response group. Among the 12 favorable response patients, five (41.7%) experienced recurrence of ATM during the followup. Patients (n = 5) who experienced relapse had a shorter duration of high-dose corticosteroid treatment (13.2 days vs. 32.9 days, p = 0.01) compared to patients who did not relapse. The mean duration of tapering-off the corticosteroid until 10 mg per day was significantly longer in non-relapse group (151.3 ± 60.8 days) than in relapse group (63.6 ± 39.4 days, p = 0.013). Conclusions: Higher disease activity in SLE and initial severe neurologic deficits might be associated with the poor outcome of ATM. Corticosteroid slowly tapering- off therapy might be helpful in preventing the recurrence of ATM.
참고문헌 (26)
- Sibley JT, "The incidence and prognosis of central nervous system disease in systemic lupus erythematosus", J Rheumatol, 19, pp.47~52 (1992)
- Bruyn GA, "Controversies in lupus : nervous system involvement", Ann Rheum Dis, 54, pp.159~167 (1995)
- "The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes", Arthritis Rheum, 42, pp.599~608 (1999)
- Kovacs B, "Transverse myelopathy in systemic lupus erythematosus : an analysis of 14 cases and review of the literature", Ann Rheum Dis, 59, pp.120~124 (2000)
- Transverse Myelitis Consortium Working Group, "Proposed diagnostic criteria and nosology of acute transverse myelitis", Neurology, 59, pp.499~505 (2002)
- D’Cruz DP, "Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease : good functional outcome and relevance of antiphospholipid antibodies", J Rheumatol, 31, pp.280~285 (2004)
- Bertsias GK, "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations : report of a task force of the EULAR standing committee for clinical affairs", Ann Rheum Dis, 69, pp.2074~2082 (2010)
- Hochberg MC, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus", Arthritis Rheum, 40, pp.1725~ (1997)
- Kirshblum SC, "Reference for the 2011 revision of the International Standards for Neurological Classification of Spinal Cord Injury", J Spinal Cord Med, 34, pp.547~554 (2011)
- Saison J, "Systemic lupus erythematosus-associated acute transverse myelitis : manifestations, treatments, outcomes, and prognostic factors in 20 patients", Lupus, 24, pp.74~81 (2015)
- Gladman DD, "Systemic lupus erythematosus disease activity index 2000", J Rheumatol, 29, pp.288~291 (2002)
- Berman M, "Acute transverse myelitis : incidence and etiologic considerations", Neurology, 31, pp.966~971 (1981)
- Jeffery DR, "Transverse myelitis : retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events", Arch Neurol, 50, pp.532~535 (1993)
- Birnbaum J, "Distinct subtypes of myelitis in systemic lupus erythematosus", Arthritis Rheum, 60, pp.3378~3387 (2009)
- Lu X, "Prognostic factors of lupus myelopathy", Lupus, 17, pp.323~328 (2008)
- Tellez-Zenteno JF, "Longitudinal myelitis associated with systemic lupus erythematosus : clinical features and magnetic resonance imaging of six cases", Lupus, 10, pp.851~856 (2001)
- Heinlein AC, "Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus", Lupus, 16, pp.823~826 (2007)
- Lavalle C, "Transverse myelitis : a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies", J Rheumatol, 17, pp.34~37 (1990)
- Chan KF, "Transverse myelopathy in SLE : clinical features and functional outcomes", Lupus, 5, pp.294~299 (1996)
- Katsiari CG, "Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation", Eur J Neurol, 18, pp.556~563 (2011)
- Jonsen A, "Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population : increased morbidity but low mortality", Rheumatology(Oxford), 41, pp.1308~1312 (2002)
- Popescu A, "Neuropsychiatric systemic lupus erythematosus", Curr Neuropharmacol, 9, pp.449~457 (2011)
- Sellner J, "EFNS guidelines on diagnosis and management of neuromyelitis optica", Eur J Neurol, 17, pp.1019~1032 (2010)
- Harisdangkul V, "Lupus transverse myelopathy : better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment", J Neurol, 242, pp.326~331 (1995)
- Wingerchuk DM, "Revised diagnostic criteria for neuromyelitis optica", Neurology, 66, pp.1485~1489 (2006)
- Chan KH, "Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese", Eur J Neurol, 16, pp.310~316 (2009)